In the liver, the hepatocyte mass is kept stable through a tight balance between hepatocyte death and proliferation that is frequently lost upon acute or chronic liver injury. Wuestefeld et al. (2013) now identify a potentially druggable target that enhances hepatocyte proliferation and promotes liver regeneration, thereby preventing liver failure.
Hepatocytes can proliferate extensively, which is critical for liver homeostasis and, even more so, liver regeneration. In severe liver diseases, however, excessive hepatocyte death may not be sufficiently compensated by normal hepatocyte proliferation, leading to loss of liver function and ultimately multiorgan failure. Thus, strategies for identifying druggable targets that could enhance liver regeneration are of great therapeutic value. Toward this aim, Wuestefeld et al. (2013) performed an RNA interference (RNAi) screen in mouse models of subacute and chronic liver injury knocking down 301 putative tumor suppressor genes previously identified in human hepatocellular carcinomas (Zender et al., 2008) . They identify a gene whose suppression leads to a robust increase in the proliferative capacity of hepatocytes, representing a potentially valuable target for future treatments.
In both liver disease models the top hit is mitogen-activated protein kinase (MKK) 4. Of the seven currently known MKKs, MKK4 (also known as SEK1) and MKK7 (SEK2) are activators of c-Jun N-terminal kinase (JNK) signaling, which regulates essential cell functions such as proliferation and survival (Haeusgen et al., 2011) . Mice deficient in MKK4 and MKK7 exhibit defects in liver development due to death and cell-cycle arrest of embryonic liver progenitors (Nishina et al., 1999; Wada et al., 2004) . By dissecting the function of MKK4 and MKK7 in hepatocytes of adult mice, Wuestefeld et al. shed new light on the regulation and function of JNK signaling in postnatal liver regeneration and unexpectedly suggest inhibition of MKK4 as a strategy for improving or restoring it.
Inhibition of MKK4 has multiple beneficial effects. First, it significantly accelerates hepatocyte proliferation, both in the fumarylacetoacetate hydrolase-deficient mouse model of subacute liver failure and after chronic liver injury with carbon tetrachloride. Second, MKK4-deficient hepatocytes are protected from Fasmediated apoptosis. Finally, MKK4 deficiency also decreases the severity of liver fibrosis. This last finding underscores the importance of hepatocyte cell cycle arrest and death as triggers of liver cirrhosis.
At the molecular level, MKK4 knockdown causes activation of JNK signaling. This finding is unexpected, considering that MKK4 is a JNK activator. As the underlying mechanism the authors identify compensatory activation of MKK7 using a combinatorial gene knockdown strategy: Concurrent knockdown of MKK7 in MKK4-deficient hepatocytes abolishes the phenotype of accelerated proliferation. Further investigations reveal that the proproliferative effect of MKK7 activation is mediated by JNK1 and its effectors ATF2 and ELK1. These findings are consistent with a model in which MKK7 is the principal activator of JNK signaling (Haeusgen et al., 2011) . Furthermore, the findings provide evidence for the emerging concept of reciprocal regulation of MKK4 and MKK7 activity (Haeusgen et al., 2011) . Because MKK4 also activates p38 signaling, which generally inhibits proliferation, it would be interesting to delineate the contribution of p38 suppression to the phenotypes observed in MKK4-deficient hepatocytes.
The authors' finding that MKK4 deficiency renders adult hepatocytes resistant to apoptosis differs from previous findings of spontaneous apoptosis of embryonic liver progenitors in MKK4-deficient mice (Nishina et al., 1999) . In addition, sustained JNK activation, as observed in MKK4-deficient hepatocytes, would have been expected to be essential for Fasinduced apoptosis (Corazza et al., 2006) , not to antagonize it. These ''contradictions'' support the notion that the effects of JNK signaling are highly cell-type and context dependent (Seki et al., 2012) .
The work by Wuestefeld et al. has several exciting therapeutic implications. Although MKK4 deletions can be found in liver cancer, their data indicate that MKK4 deficiency alone is insufficient to cause hepatocyte proliferation or liver cancer. Instead, MKK4 depletion accelerates regeneration that has already been initiated, making it more efficient. It also protects dividing hepatocytes from premature death. Transient MKK4 inhibition therefore has potential in the therapy of acute liver failure (Figure 1 ). This would require fast-acting MKK4 blockage to facilitate restoration of a critical hepatocyte mass before aggravation of the illness to multiorgan failure (Ido et al., 2011) . For this, antisense oligonucleotides could be used that reach hepatocytes and knock down targeted genes within hours after intravenous injection (Ng et al., 2012) . Alternatively, specific small-molecule inhibitors of MKK4 could be developed.
Another finding of potentially great impact is the ability of MKK4-deficient hepatocytes to engraft and repopulate mice after extended culture. Typically, mouse hepatocytes lose their engraftment potential after only 3-4 days in culture, but MKK4-deficient hepatocytes could be transplanted even after 12 days ex vivo. If this feature were replicated in human cells, it would be particularly useful for improving engraftment and posttransplant expansion of hepatocyte-like cells generated by in vitro differentiation of pluripotent stem cells. In addition, exposing MKK4-deficient hepatocytes to growth factors may allow their in vitro expansion, a feat liver researchers have been working for decades to achieve.
It appears unlikely that MKK4 would have been chosen as a therapeutic target based on hypotheses derived from pre-existing studies. The success of this study once again underscores the power of unbiased ''blind'' screens, particularly those that can be carried out in vivo in a clinically relevant system. Liver injury frequently causes impaired hepatocyte replication and apoptosis, leading to hepatic failure and death, or severe fibrosis. Inhibition of MKK4, as demonstrated by Wuestefeld et al. (2013) , accelerates the replication of hepatocytes and prevents their apoptosis, thereby permitting successful tissue regeneration.
